Skip to main content
CRMD
NASDAQ Life Sciences

CEO Joseph Todisco Buys 80,000 CRMD Shares for $391,200 on the Open Market

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$4.61
Mkt Cap
$370.645M
52W Low
$4.65
52W High
$13.02
52W Position info
0.9% below low
Off High info
65% below high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

CRMD is trading near its 52-week low of $4.65 (0.9% below the low).

Summary

CorMedix CEO Joseph Todisco bought 80,000 shares on the open market at a weighted average of $4.89, about $391,200, lifting his direct stake to 854,749 shares. The buy comes days after a revenue-beating Q3 that nonetheless showed DefenCath sales down on the CMS reset and 2027 guidance suspended.


Key Events · Ownership and Investor Activity · CRMD

  • CEO Open-Market Purchase

    Joseph Todisco bought 80,000 shares on 2026-11-13 at a weighted average price of $4.89, for a total of $391,200, in trades ranging from $4.85 to $5.00.

  • Stake Rises to 854,749 Shares

    The purchase lifts the CEO's direct holdings to 854,749 shares, all directly owned.

  • Buy Follows Mixed Q3

    The purchase comes four days after the Q3 2026 report showing $54.5M revenue above the $51.2M consensus, but DefenCath sales down to $17.2M on the CMS reimbursement reset and 2027 DefenCath guidance suspended.

  • Timing Near 52-Week Low

    The stock trades near its 52-week low of $4.65, and the CEO bought at $4.85-$5.00, above the current $4.61 price.


Analysis · CRMD · Life Sciences

Why it matters: the CEO put $391,200 of his own money into the stock at a weighted average of $4.89, with trades executed from $4.85 to $5.00 — genuine open-market buying, not an option exercise or grant. The purchase lands days after a Q3 report that beat revenue consensus ($54.5M) but showed DefenCath sales falling to $17.2M on the CMS reimbursement reset, an unremediated material weakness, and suspended 2027 DefenCath guidance, and while the stock trades near its 52-week low of $4.65. It also comes as CorMedix is committing $145M in cash plus 14,583,333 shares for Heron Therapeutics' assets. The dollar size is modest relative to the company, so this is a confidence gesture rather than a thesis-changer, but a CEO buying at the low after a mixed quarter is worth noting.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRMD was trading at $4.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $370.6M. The 52-week trading range was $4.65 to $13.02. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRMD - Latest Insights

CRMD
Nov 12, 2026, 8:21 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.15
Real-time Price: $4.85 info
Change: -$0.300 (-6%) info
Market Cap: $370.645M info
CRMD
Nov 12, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.25
Real-time Price: $4.85 info
Change: -$0.400 (-8%) info
Market Cap: $370.645M info
CRMD
Nov 12, 2026, 7:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.25
Real-time Price: $4.85 info
Change: -$0.400 (-8%) info
Market Cap: $370.645M info
CRMD
Nov 09, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $5.50
Real-time Price: $4.85 info
Change: -$0.650 (-12%) info
Market Cap: $370.645M info
CRMD
Nov 02, 2026, 7:39 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.50
Real-time Price: $4.85 info
Change: -$0.650 (-12%) info
Market Cap: $370.645M info